Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.

BMC Cancer · 2022 · PMC9719636 · PMID 36463104

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Analysis of variation in MDSCs levels along the treatment and correlation with CBR showed a trend towards decreased levels of MDSCs in patients that experienced a clinical benefit (CB) as compared to patients that suffered PD (Table 4 ).

also in 53,322 other papers

a clear trendno p-value reported

Interestingly, MDSCs decreased along treatment implementation in the CB group versus PD group with a clear trend at C3 that seem less obvious at C6.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.